Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Vertex Pharmaceuticals Incorporated

Pfizer vs. Vertex: A Decade of R&D Investment

__timestampPfizer Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 20148393000000855506000
Thursday, January 1, 20157690000000996170000
Friday, January 1, 201678720000001047690000
Sunday, January 1, 201776570000001324625000
Monday, January 1, 201880060000001416476000
Tuesday, January 1, 201986500000001754540000
Wednesday, January 1, 202094050000001829537000
Friday, January 1, 2021138290000003051100000
Saturday, January 1, 2022114280000002540300000
Sunday, January 1, 2023106790000003162900000
Monday, January 1, 2024109300000003630300000
Loading chart...

Igniting the spark of knowledge

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Pfizer Inc. and Vertex Pharmaceuticals Incorporated have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Pfizer's R&D expenses have consistently surpassed those of Vertex, peaking in 2021 with a 38% increase from 2020. This surge reflects Pfizer's aggressive strategy to maintain its competitive edge. Meanwhile, Vertex has shown a steady upward trend, with a notable 73% increase in R&D spending from 2014 to 2023, highlighting its focus on niche markets and specialized treatments. As the pharmaceutical landscape continues to shift, these spending patterns underscore the strategic priorities of each company, offering insights into their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025